Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and nab-paclitaxel in high-risk non-muscle-invasive bladder cancer
NCT05418309Phase 2Unknown
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Dec 2021
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in Non-muscle-invasive bladder cancer (NMIBC), sponsored by The Second Hospital of Tianjin Medical University. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05418309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05418309.